c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Found 142 products of "c-Met/HGFR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Foretinib phosphate
CAS:Foretinib phosphate, an oral MET/VEGFR2 inhibitor GSK1363089, may curb tumor growth and spread.Formula:C34H40F2N4O14P2Color and Shape:SolidMolecular weight:828.65SCR-1481B1
CAS:SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitorFormula:C32H40ClF2N6O13PPurity:98.07%Color and Shape:SolidMolecular weight:821.12Ref: TM-T5349
1mg35.00€2mg50.00€5mg74.00€10mg113.00€25mg200.00€50mg333.00€100mg495.00€1mL*10mM (DMSO)102.00€Capmatinib 2HCl
CAS:Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.Formula:C23H19Cl2FN6OPurity:98.80%Color and Shape:SolidMolecular weight:485.34Ref: TM-T4260
2mg34.00€5mg49.00€10mg64.00€25mg84.00€50mg92.00€100mg126.00€500mg303.00€1mL*10mM (DMSO)58.00€BMS-2
CAS:BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.Formula:C25H16F2N4O3Purity:98.33%Color and Shape:SolidMolecular weight:458.42Ref: TM-T8326
1mg67.00€2mg88.00€5mg148.00€10mg230.00€25mg430.00€50mg622.00€100mg898.00€1mL*10mM (DMSO)170.00€PF-04217903
CAS:MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.Formula:C19H16N8OPurity:98.41% - 98.55%Color and Shape:SolidMolecular weight:372.38S49076 HCl
CAS:S49076 HCl (S-49076 Hydrochloride) is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3.Formula:C22H18ClN3O5Purity:98%Color and Shape:SolidMolecular weight:439.85Foretinib
CAS:Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Formula:C34H34F2N4O6Purity:98.07% - 99.68%Color and Shape:SolidMolecular weight:632.65Ref: TM-T3113
2mg39.00€5mg57.00€10mg79.00€25mg133.00€50mg207.00€100mg354.00€500mg848.00€1mL*10mM (DMSO)79.00€BMS817378
CAS:BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).Formula:C24H18ClF2N4O7PPurity:>99.99%Color and Shape:SolidMolecular weight:578.85Merestinib dihydrochloride
CAS:Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.Formula:C30H24Cl2F2N6O3Color and Shape:SolidMolecular weight:625.45Pamufetinib mesylate
CAS:Pamufetinib mesylate (TAS-115 mesylate) is a VEGFR antagonist and c-Met inhibitor used in the study of cancer and respiratory diseases.Formula:C28H27FN4O7S2Purity:98.91%Color and Shape:SolidMolecular weight:614.67Altiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Formula:C26H21F3N4O4Purity:99.67% - 99.75%Color and Shape:SolidMolecular weight:510.46Capmatinib 2HCl.H2O
CAS:Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Formula:C23H21Cl2FN6O2Purity:99.77%Color and Shape:SolidMolecular weight:503.36Ref: TM-T8825
2mg34.00€5mg48.00€10mg63.00€25mg84.00€50mg92.00€100mg126.00€500mg250.00€1mL*10mM (DMSO)50.00€Tivantinib
CAS:Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.Formula:C23H19N3O2Purity:98% - 99.41%Color and Shape:SolidMolecular weight:369.42Ningetinib
CAS:Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Formula:C31H29FN4O5Purity:99.95% - 99.98%Color and Shape:SolidMolecular weight:556.58NVP-BVU972
CAS:NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.Formula:C20H16N6Purity:97.24% - >99.99%Color and Shape:SolidMolecular weight:340.38Ref: TM-T2680
2mg44.00€5mg74.00€10mg97.00€25mg178.00€50mg255.00€100mg359.00€200mg510.00€1mL*10mM (DMSO)84.00€NPS-1034
CAS:NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.Formula:C31H23F2N5O3Purity:98.48%Color and Shape:SolidMolecular weight:551.54Ref: TM-T6907
1mg34.00€2mg46.00€5mg66.00€10mg92.00€25mg167.00€50mg245.00€100mg356.00€200mg530.00€1mL*10mM (DMSO)82.00€Hepln-13
CAS:Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.Formula:C17H13BrN2Purity:97.67%Color and Shape:SolidMolecular weight:325.2Ref: TM-T25492
1mg35.00€2mg52.00€5mg80.00€10mg119.00€25mg231.00€50mg344.00€100mg480.00€200mg663.00€1mL*10mM (DMSO)92.00€AMG-337
CAS:AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).Formula:C23H22FN7O3Purity:99.26% - 99.9%Color and Shape:SolidMolecular weight:463.46Ref: TM-T3209
1mg40.00€2mg52.00€5mg85.00€10mg124.00€25mg197.00€50mg350.00€100mg522.00€200mg748.00€1mL*10mM (DMSO)86.00€X-376
CAS:X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.Formula:C25H25Cl2FN6O3Purity:97.87%Color and Shape:SolidMolecular weight:547.41Ref: TM-T3550
1mg35.00€2mg50.00€5mg87.00€10mg119.00€25mg258.00€50mg427.00€100mg582.00€1mL*10mM (DMSO)105.00€AMG-208
CAS:AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.Formula:C22H17N5O2Purity:98.56%Color and Shape:SolidMolecular weight:383.4
